Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08DWM
|
|||
| Former ID |
DIB000597
|
|||
| Drug Name |
Gp100:209-217(210M) peptide vaccine
|
|||
| Synonyms |
Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Company |
National Cancer Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocytes lineage-specific antigen GP100 (PMEL) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00003895) Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 476335). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.